Urologia Internationalis
Original Paper
CA9 Expression as a Prognostic Factor in Renal Clear Cell CarcinomaSoyupak B.a · Erdoğan Ş.b · Ergin M.b · Seydaoğlu G.c · Kuzgunbay B.a · Tansuğ Z.aDepartments of aUrology, bPathology, and cBiostatistics, Çukurova University Medical Faculty, Adana, Turkey
Keywords: CA9Renal cell carcinoma |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 27, 2004
Accepted: October 11, 2004
Published online: January 28, 2005
Issue release date: January 2005
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 5
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Introduction: We investigated whether CA9 protein could be used as a prognostic tumor marker as well as a diagnostic biomarker in renal clear cell carcinoma. Materials and Methods: Nephrectomy specimens from 92 patients were used in this study. 80 of these were renal cell carcinomas, 10 adenomas and 2 oncocytomas. Of the renal cell carcinomas, 67 were clear cell carcinomas. Immunohistochemical analysis using CA9 monoclonal antibody (M75) was performed on paraffin-embedded specimens. CA9 staining was correlated with tumor stage, grade, lymph node involvement, distant metastasis and cumulative survival time. Results: CA9 was present in 91.2% of clear cell carcinomas. Low staining was a poor prognostic factor, and conversely high staining a good prognostic one. CA9 expression was found to be the best prognostic factor when compared with T stage and grade. Even in low-grade and stage tumors, the presence of low expression correlated with lowered survival times. Conclusions: On the basis of our study, CA9 is a significant molecular marker in renal clear cell carcinomas. Decreased CA9 expression is independently associated with poor survival. CA9 can be used to predict clinical outcome and identify high-risk patients in need for adjuvant immunotherapy and CA9 targeted therapies.
© 2005 S. Karger AG, Basel
Related Articles:
References
-
Novick AJ, Campbell SC: Renal tumors; in Walsh P (ed): Campell’s Urology. Philadelphia, Saunders, 2002, pp 2672–2731.
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Wars E, et al: Cancer statistics. CA Cancer J Clin 2004;54:8–29.
- Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628–1631.
- Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, Moulinoux JP, Guille F, Ramee MP, Lobel B: Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55:501–505.
- Tsui KH, Shvarts O, Smith RB, Figlin RA, de Kernion JB, Belldegrun A: Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000;163:1090–1095.
- Bui MH, Zisman A, Pantuck AJ, Han KR, Wieder J, Belldegrun AS: Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther 2001;1:565–575.
- Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface ransmembrane carbonic anhydrases in human cancer. Am J Pathol 2001;158:905–919.
- Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V: Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993;54:268–274.
- Oosterwijk E, Ruiter D, Joedemaeker P: Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489–494.
- Murakami Y, Kanda K, Tsuji M, Kanayama H, Kagawa S: CA9 gene expression as a potential biomarker in renal cell carcinoma. BJU Int 1999;83:743–747.
- Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y, Oosterwijk E: MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741–746.
- Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ: Identification of the CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997;57:2827–2831.
- Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Path 1982;6:655–663.
- Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J: A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620–626.
- Bui MH, Seligson D, Han K, Pantuck A, Dorey F, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerma M, Palotie A, Figlin R, Belldegrun A: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 2003;9(2):802–811.
- Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova Manetta A, Berman ML, DiSaia PJ, Stanbridge EJ: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994;145:598–609.
- Bui MH, Visapaa H, Seligson D, Kim H, Han K, Huang Y, Horvath S, Stanbridge E, Palotie A, Figlin R, Belldegrun A: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004;171:2461–2466.
- Zavada J, Zavadova Z, Zatovicova M, Hyrsl L, Kawaciuk I: Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 2003;89:1067–1071.
- Jocham D, Richter A, Hoffman L, Iwig K, Fahlenkamp D, Zakrzewski G, Schmidt E, Dannenberg T, Lehmacher W, von Wieterheim J, Doehn C: Adjuvant autologous renal tumor cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 2004;363:594–599.
- Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgorous G, Welt S, Finn RD, Morissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998;4:2729–2739.
- Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A: Induction of G250-targeted and T-cell mediatedantitumor activity agaist renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 2001;61:7925–7933.
Article / Publication Details
Received: May 27, 2004
Accepted: October 11, 2004
Published online: January 28, 2005
Issue release date: January 2005
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 5
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
